ROTABLATOR VS. ANGIOPLASTY: REINTERVENTION RATE 11% HIGHER
This article was originally published in The Gray Sheet
Executive Summary
ROTABLATOR VS. ANGIOPLASTY: REINTERVENTION RATE 11% HIGHER for rotational atherectomy with the Rotablator than for percutaneous transluminal coronary angioplasty when performed on complex lesions, Michel Vandormael, Heart Center & Red Cross Hospital, Frankfurt, Germany, et al., reported Nov. 15 at the American Heart Association's Scientific Sessions in Dallas. The researchers' conclusion was based on nine-month follow-up of a 620-patient, single-center randomized trial investigating procedural and angiographic results in patients treated with rotational atherectomy, excimer laser angioplasty, and PTCA.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.